InnovAge Holding Corp 10-Q for FY2027 Q1
InnovAge Holding Corp. (INNV)
10-Q
2026-11-03
For: 2026-09-30
View Original
Added on
November 03, 2026
About this 10-Q
InnovAge Holding Corp filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2027 Q1).
InnovAge reported revenue of $264.7 million, up 12.1%, and net income of $20.9 million for the three months ended September 30, 2026, versus $7.7 million a year earlier. It expects fiscal 2027 margin pressure from Medicaid rate pressures. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $264.76M
- up 12.1% from $236.11M a year earlier
- Net income
- $19.55M
- up 143.8% from net income of $8.02M a year earlier
- Diluted EPS
- $0.14
- up 133.3% from $0.06 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________
FORM 10-Q
_______________________________________________________
(Mark One)
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2026
or
EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number: 001-40159
_______________________________________________________
(Exact name of registrant as specified in its charter)
_______________________________________________________
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification Number) | ||||
(Address of Principal Executive Offices) | (Zip Code) | ||||
(844 ) 803-8745
(Registrant’s telephone number, including area code)
_______________________________________________________
Securities registered pursuant to Section 12(b) of the Securities Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | o | x | |||||||||||||||
| Non-accelerated filer | o | Smaller reporting company | Emerging growth company | ||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of October 30, 2026, there were 136,456,506 of the registrant’s common stock outstanding.
TABLE OF CONTENTS
| Page | ||||||||
2
InnovAge Holding Corp. and Subsidiaries
Quarterly Report on Form 10-Q
For the quarterly period ended September 30, 2026
Cautionary Note on Forward-Looking Statements
Throughout this Quarterly Report on Form 10-Q, we make “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This Quarterly Report contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth opportunities or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including:
•the viability of our growth strategy, including our ability to find suitable geographies for new centers and obtain licenses to open such centers, our ability to ramp up our de novo centers and the outcome of our organizational and enterprise efficiency initiatives;
•our ability to identify, successfully complete and integrate acquisitions, joint ventures and other strategic partnerships;
•our ability to attract new participants and retain existing participants to implement our growth strategy;
•the impact on our business from ongoing macroeconomic, geopolitical and industry-related challenges, including labor shortages, labor competition, high inflation, and supply chain disruptions as a result of tariffs and trade disputes;
•the risk that the cost of providing services will exceed our compensation under the Program of All Inclusive Care for the Elderly (“PACE”);
•our increased costs and expenditures and our inability to execute or realize the benefits of our clinical and operational value initiatives;
•the dependence of our revenues and operations upon a limited number of government payors, which exposes us to the risk of government funding reductions, legislative changes and federal and state budgetary pressures;
•reductions in PACE reimbursement rates;
•the results of periodic inspections, reviews, audits and investigations under the federal and state government programs, and our ability to sufficiently cure any deficiencies identified by the respective federal and state government programs;
•the adverse impact of legal proceedings, enforcement actions and litigation and disputes;
•the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants;
•our dependence on our senior management team and other key employees;
•our ability to compete in the healthcare industry;
•the concentration of a significant percentage of our operations in the States of California and Colorado;
•the difficulty to predict our future operating results, which could cause such results to fall below any guidance, targets or goals we provide;
•the impact of failures by our suppliers to meet our needs, or limitations on our ability to effectively access new technology or medical products;
•our ability to manage our operations effectively, execute our business plan, maintain effective levels of service and participant satisfaction and adequately address competitive challenges;
•the impact on our business of security breaches, loss of data or other disruptions, including disruptions in our disaster recovery systems, causing the compromise of sensitive information or preventing us from accessing critical information;
•our ability to accurately estimate incurred but not reported medical expense or the risk scores of our participants;
•our ability to adhere to complex and changing government laws and regulations in the healthcare industry, including U.S. Healthcare reform, the regulation of the corporate practice of medicine and the Health Information
3
Technology for Economic and Clinical Health Act of 2009 (the “HITECH Act”), and their implementing regulations (collectively, “HIPAA”), and other privacy laws and regulations in the healthcare industry;
•our status as a “controlled company”;
•the volatility of our stock price; and
•other factors disclosed in the section entitled “Risk Factors” in our Annual Report for the year ended June 30, 2026 filed with the Securities and Exchange Commission (the “SEC”) on September 9, 2026 ("2026 10-K"), and our subsequent filings with the SEC.
We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.
Unless otherwise specified or unless the context requires otherwise, all references in this Quarterly Report on Form 10-Q to “InnovAge,” “the Company,” “we,” “us,” and “our,” or similar references, refer to InnovAge Holding Corp. and our consolidated subsidiaries.
4
PART I —FINANCIAL INFORMATION
Item 1. Financial Statements
INNOVAGE HOLDING CORP. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except shares and par value data)
(Unaudited)
| September 30, 2026 | June 30, 2026 | ||||||||||
| Assets | |||||||||||
| Current Assets | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Short-term investments | |||||||||||
| Restricted cash | |||||||||||
| Accounts receivable | |||||||||||
| Prepaid expenses and other | |||||||||||
| Income tax receivable | |||||||||||
| Total current assets | |||||||||||
| Noncurrent Assets | |||||||||||
| Property and equipment, net | |||||||||||
| Operating lease assets | |||||||||||
| Deposits and other | |||||||||||
| Goodwill | |||||||||||
| Other intangible assets, net | |||||||||||
| Total noncurrent assets | |||||||||||
| Total assets | $ | $ | |||||||||
| Liabilities and Stockholders' Equity | |||||||||||
| Current Liabilities | |||||||||||
| Accounts payable and accrued expenses | $ | $ | |||||||||
| Reported and estimated claims | |||||||||||
| Due to Medicaid and Medicare | |||||||||||
| Current portion of long-term debt | |||||||||||
| Current portion of finance lease obligations | |||||||||||
| Current portion of operating lease obligations | |||||||||||
| Total current liabilities | |||||||||||
| Noncurrent Liabilities | |||||||||||
| Deferred tax liability, net | |||||||||||
| Finance lease obligations | |||||||||||
| Operating lease obligations | |||||||||||
| Other noncurrent liabilities | |||||||||||
| Long-term debt, net of debt issuance costs | |||||||||||
| Total liabilities | |||||||||||
| Commitments and Contingencies (See Note 9) | |||||||||||
| Redeemable Noncontrolling Interests (See Note 4) | |||||||||||
| Stockholders’ Equity | |||||||||||
Common stock, $ | |||||||||||
Treasury stock at cost, | ( | ( | |||||||||
| Additional paid-in capital | |||||||||||
| Retained deficit | ( | ( | |||||||||
| Total InnovAge Holding Corp. | |||||||||||
| Noncontrolling interests | |||||||||||
| Total stockholders’ equity | |||||||||||
| Total liabilities and stockholders’ equity | $ | $ | |||||||||
5
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
INNOVAGE HOLDING CORP. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(In thousands, except number of shares and per share data)
(Unaudited)
| Three Months Ended September 30, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Capitation revenue | $ | $ | |||||||||||||||||||||
| Other service revenue | |||||||||||||||||||||||
| Total revenues | |||||||||||||||||||||||
| Expenses | |||||||||||||||||||||||
| External provider costs | |||||||||||||||||||||||
| Cost of care, excluding depreciation and amortization | |||||||||||||||||||||||
| Sales and marketing | |||||||||||||||||||||||
| Corporate, general and administrative | |||||||||||||||||||||||
| Depreciation and amortization | |||||||||||||||||||||||
| Loss on assets held for sale | |||||||||||||||||||||||
| Total expenses | |||||||||||||||||||||||
| Operating Income | |||||||||||||||||||||||
| Other Income (Expense) | |||||||||||||||||||||||
| Interest expense, net | ( | ( | |||||||||||||||||||||
Other income, net | |||||||||||||||||||||||
| Total other expense | ( | ( | |||||||||||||||||||||
| Income Before Income Taxes | |||||||||||||||||||||||
Provision (Benefit) for Income Taxes | ( | ||||||||||||||||||||||
| Net Income | |||||||||||||||||||||||
| Less: net income (loss) attributable to noncontrolling interests | ( | ||||||||||||||||||||||
| Net Income Attributable to InnovAge Holding Corp. | $ | $ | |||||||||||||||||||||
| Weighted-average number of common shares outstanding - basic | |||||||||||||||||||||||
| Weighted-average number of common shares outstanding - diluted | |||||||||||||||||||||||
| Net income per share - basic | $ | $ | |||||||||||||||||||||
| Net income per share - diluted | $ | $ | |||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
INNOVAGE HOLDING CORP. AND SUBSIDIARIES
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
(Unaudited)
| Three Months Ended September 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Stock | Additional Paid-in Capital | Retained Earnings (Deficit) | Treasury Stock | Noncontrolling Interests | Total Permanent Stockholders' Equity | Redeemable Noncontrolling Interests (Temporary Equity) | Net Income | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, June 30, 2026 | $ | $ | $ | ( | $ | ( | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tax withholding related to net share settlements of stock-based compensation awards | ( | — | ( | — | — | — | — | ( | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
Distributions to joint venture | — | — | — | — | — | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | — | — | — | — | — | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, September 30, 2026 | $ | $ | $ | ( | $ | ( | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended September 30, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Stock | Additional Paid-in Capital | Retained Earnings (Deficit) | Treasury Stock | Noncontrolling Interests | Total Permanent Stockholders' Equity | Redeemable Noncontrolling Interests (Temporary Equity) | Net Income | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, June 30, 2025 | $ | $ | $ | ( | $ | ( | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tax withholding related to net share settlements of stock-based compensation awards | ( | — | ( | — | — | — | — | ( | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Contributions from joint venture | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income (loss) | — | — | — | — | — | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, September 30, 2025 | $ | $ | $ | ( | $ | ( | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
8
INNOVAGE HOLDING CORP. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
| Three Months Ended September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Operating Activities | |||||||||||
| Net income | $ | $ | |||||||||
| Adjustments to reconcile net income to net cash provided by operating activities | |||||||||||
| Loss (gain) on disposal of assets | ( | ||||||||||
| Depreciation and amortization | |||||||||||
| Operating lease rentals | |||||||||||
| Loss on assets held for sale | |||||||||||
| Amortization of deferred financing costs | |||||||||||
| Stock-based compensation | |||||||||||
| Deferred income taxes | ( | ||||||||||
| Other, net | |||||||||||
| Changes in operating assets and liabilities | |||||||||||
| Accounts receivable | |||||||||||
| Prepaid expenses and other | ( | ( | |||||||||
| Income tax receivable | |||||||||||
| Deposits and other | ( | ( | |||||||||
| Accounts payable and accrued expenses | ( | ( | |||||||||
| Reported and estimated claims | ( | ( | |||||||||
| Due to Medicaid and Medicare | |||||||||||
| Operating lease liabilities | ( | ( | |||||||||
Net cash provided by operating activities | |||||||||||
| Investing Activities | |||||||||||
| Purchases of property and equipment | ( | ( | |||||||||
| Purchases of short-term investments | ( | ( | |||||||||
| Proceeds from sale of assets held for sale | |||||||||||
Net cash used in investing activities | ( | ( | |||||||||
| Financing Activities | |||||||||||
| Payments for finance lease obligations | ( | ( | |||||||||
| Principal payments on long-term debt | ( | ( | |||||||||
| Proceeds from the issuance of long-term debt | |||||||||||
| Payments on financing costs | ( | ||||||||||
| Contribution from joint venture partner | |||||||||||
| Distribution to joint venture partner | ( | ||||||||||
| Taxes paid related to net settlements of stock-based compensation awards | ( | ( | |||||||||
| Net cash used in financing activities | ( | ( | |||||||||
Net change in cash, cash equivalents and restricted cash including cash of $ | |||||||||||
| Less: change in cash and restricted cash reclassified to assets held for sale | ( | ||||||||||
INCREASE IN CASH, CASH EQUIVALENTS & RESTRICTED CASH | |||||||||||
9
| CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD | |||||||||||
| CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD | $ | $ | |||||||||
| Supplemental Cash Flows Information | |||||||||||
| Interest paid | $ | $ | |||||||||
| Income taxes paid | $ | $ | |||||||||
| Property and equipment included in accounts payable | $ | $ | |||||||||
| Property and equipment purchased under finance leases | $ | $ | |||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
10
INNOVAGE HOLDING CORP. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1: Business
InnovAge Holding Corp. and its subsidiaries (“InnovAge” or the "Company") are headquartered in Denver, Colorado. The purpose of the Company’s participant-centered care delivery approach is to improve the quality of care the Company’s participants receive, while keeping them in their homes for as long as safely possible. Through the Company’s Program of All-Inclusive Care for the Elderly (“PACE”), the Company fulfills a broad range of medical and ancillary services for seniors, including in-center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management, including pharmacy services. The Company manages its business as one reportable segment, PACE.
As of September 30, 2026, the Company served approximately 8,420 PACE participants, making it the largest PACE provider in the United States of America (the “U.S.”) based upon participants served, and operated 20 PACE centers across California, Colorado, Florida, New Mexico, Pennsylvania and Virginia.
PACE is a fully-capitated managed care program, which serves the frail elderly, and predominantly dual-eligible, population in a community-based service model. The Company defines dual-eligible seniors as individuals who are 55+ and qualify for benefits under both Medicare and Medicaid. InnovAge provides all needed healthcare services through an all-inclusive, coordinated model of care, and the Company is at risk for 100 % of healthcare costs incurred with respect to the care of its participants. PACE programs receive capitation payments directly from Medicare Parts C and D, Medicaid, Veterans Administration (“VA”), and private pay sources. Additionally, under the Medicare Prescription Drug Plan, the Centers for Medicare and Medicaid Services (“CMS”) share part of the risk for providing prescription medication to the Company’s participants.
Note 2: Summary of Significant Accounting Policies
The Company described its significant accounting policies in Note 2, “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements in its Annual Report on Form 10-K for the year ended June 30, 2026 (“2026 10-K”). There were no significant changes to those accounting policies during the three months ended September 30, 2026.
Basis of Preparation and Principles of Consolidation
The unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended June 30, 2026. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. The condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and variable interest entities (“VIEs”) for which it is the primary beneficiary and entities for which it is the controlling general partner. All intercompany accounts and transactions have been eliminated in consolidation.
The Company does not have any components of comprehensive income and comprehensive income is equal to net income reported in the statements of operations for all periods presented.
11
Property and Equipment
Property and equipment were comprised of the following as of September 30, 2026 and June 30, 2026:
| dollars in thousands | Estimated Useful Lives | September 30, 2026 | June 30, 2026 | ||||||||||||||
| Land | N/A | $ | $ | ||||||||||||||
| Buildings and leasehold improvements | |||||||||||||||||
| Software | |||||||||||||||||
| Equipment and vehicles | |||||||||||||||||
| Construction in progress | N/A | ||||||||||||||||
| Less: accumulated depreciation and amortization | ( | ( | |||||||||||||||
| Total property and equipment, net | $ | $ | |||||||||||||||
Depreciation of $5.5 million and $4.9 million was recorded during the three months ended September 30, 2026 and 2025, respectively.
Recent Accounting Pronouncements Not Yet Adopted
Disaggregation of Income Statement Expenses
In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40). ASU 2024-03 requires that each interim and annual reporting period, an entity disclose more information about the components of certain expense captions than is currently disclosed in the financial statements. As revised by ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures, the provisions of ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effects this guidance will have on its condensed consolidated financial statements.
Interim Reporting
In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the applicability of the interim reporting guidance, the types of interim reporting, and the form and content of interim financial statements in accordance with U.S. GAAP. Per the FASB, the amendment does not intend to change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements but rather provide clarity and improve navigability of the existing interim reporting requirements. The update will be effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is assessing the effect of this update on its condensed consolidated financial statements and related disclosures.
The Company does not expect that any other recently issued accounting guidance will have a significant effect on its condensed consolidated financial statements.
Note 3: Revenue Recognition
Capitation Revenue and Accounts Receivable
The Company's revenues are based on the estimated per member, per month ("PMPM") amounts the Company expects to be entitled to receive from the capitated fees per participant that are paid monthly by Medicaid, Medicare, the VA, and private pay sources. Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. VA is included in “Private Pay and other” and is also capitated. Private pay includes direct payments from participants who do not qualify for the full capitated rate and have to pay all or a portion of the capitated rate. Costs to obtain contracts consist of sales commissions for new enrollees and are included in Deposits and other on the Company's condensed consolidated balance sheets. These costs are amortized over a three-year period which corresponds to the
12
average time a participant is enrolled in the PACE program. As of September 30, 2026 and June 30, 2026, contract assets included within prepaid expenses and other and deposits and other were $4.8 million and $4.7 million, respectively.
The Company disaggregates capitation revenue from the following sources for the three months ended:
| September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Medicaid | % | % | |||||||||
| Medicare | % | % | |||||||||
| Private pay and other | *% | *% | |||||||||
| Total | % | % | |||||||||
*Less than 1%
The Company provides comprehensive healthcare services to participants on the basis of capitated or fixed fees per participant that are paid monthly by Medicare, Medicaid, the VA and private pay sources. The Company's accounts receivable as of September 30, 2026 and June 30, 2026 were primarily from capitation revenue arrangements. The concentration of receivables from participants and third-party payers was as follows:
| September 30, 2026 | June 30, 2026 | ||||||||||
| Medicaid | % | % | |||||||||
| Medicare | % | % | |||||||||
| Private pay and other | % | % | |||||||||
| Total | % | % | |||||||||
The Company records accounts receivable at net realizable value based upon the estimated amounts the Company expects to be entitled to receive from Medicare, Medicaid, the VA and private pay sources. Estimated reimbursement amounts are adjusted in future periods as final settlements are determined.
Laws and regulations governing the Medicare and Medicaid programs are complex and subject to change, as well as government review. Failure to comply with these laws can expose the entity to significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. See Note 9, “Commitments and Contingencies.”
Note 4: Investments
Redeemable Noncontrolling Interest
InnovAge Sacramento
On March 18, 2019, the Company entered into a joint venture with Adventist Health System/West (“Adventist”) and Eskaton Properties, Incorporated (“Eskaton”) relating to InnovAge California PACE - Sacramento ("InnovAge Sacramento"). As of each of September 30, 2026, the Company held a 60 % membership interest in the joint venture and Adventist and Eskaton held 26.35 % and 13.65 %, respectively. As a result, the joint venture’s results are consolidated in the Company’s condensed consolidated financial statements.
The InnovAge California PACE-Sacramento LLC Limited Liability Company Agreement (the “JV Agreement”) includes numerous provisions whereby, if certain conditions are met, the joint venture may be required to purchase, at fair market value, certain members’ interests or certain members may be required to purchase, at fair market value, the interests of certain other members. The Company’s investment in InnovAge Sacramento includes a put right for the noncontrolling interest holders to require the Company to repurchase the interest of the noncontrolling interest holders at fair value, after the initial term of the management services agreement in 2028. As of September 30, 2026, none of the conditions specified in the JV Agreement had been met. Accordingly, these put rights held by the noncontrolling interests of the joint venture are required to be presented as temporary equity and are recorded as redeemable noncontrolling interests on the Company's condensed consolidated balance sheets. As of September 30, 2026 and June 30, 2026, the Company's redeemable noncontrolling interest was recorded at a fair value of $31.3 million and $30.0 million, respectively.
13
Note 5: Fair Value Measurements
Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants, at the measurement date. A fair value hierarchy was established that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources outside the reporting entity. Unobservable inputs are inputs that reflect the Company’s own assumptions based on market data and assumptions that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The sensitivity to changes in inputs and their impact on fair value measurements can be significant.
The three levels of inputs that may be used to measure fair value are:
Level 1Unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date
Level 2Quoted prices in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the assets or liabilities
Level 3Unobservable inputs to the valuation techniques that are significant to the fair value measurements of the assets or liabilities
Recurring Measurements
The following table shows the Company’s short-term investments that are measured and accounted for at fair value on a recurring basis as of September 30, 2026 and June 30, 2026:
| September 30, 2026 | |||||||||||||||||
| in thousands | Amortized Cost | Unrealized Gain | Fair Value | ||||||||||||||
| Level 1 | |||||||||||||||||
| Mutual funds | $ | $ | $ | ||||||||||||||
| Total short-term investments | $ | $ | $ | ||||||||||||||
| June 30, 2026 | |||||||||||||||||
| in thousands | Amortized Cost | Unrealized Gain | Fair Value | ||||||||||||||
| Level 1 | |||||||||||||||||
| Mutual funds | $ | $ | $ | ||||||||||||||
| Total short-term investments | $ | $ | $ | ||||||||||||||
The Company’s investment in InnovAge Sacramento includes a put right for the noncontrolling interest holders to require the Company to repurchase the interest of the noncontrolling interest holders at fair value, after the initial term of the management services agreement in 2028. As a result, at each fiscal period end the Company reports this put right at the greater of (i) carrying value of the redeemable noncontrolling interest or (ii) fair value of the redeemable noncontrolling interest. Because this asset does not have observable inputs, Level 3 inputs are used to measure fair value. The fair value of the redeemable noncontrolling interest is determined utilizing a discounted cash flow model. As of September 30, 2026 and June 30, 2026, the Company’s redeemable noncontrolling interest was recorded at fair value of $31.3 million and $30.0 million, respectively.
There were no transfers in and out of Level 3 during the three months ended September 30, 2026 and 2025. The Company’s policy is to recognize transfers as of the actual date of the event or change in circumstances.
14
Note 6: Goodwill and Intangible Assets
Goodwill represents the excess of cost over the fair value of net assets acquired. The Company had goodwill of $142.0
Pursuant to ASC 350, “Intangibles – Goodwill and Other,” the Company reviews the recoverability of goodwill annually as of April 1 or whenever significant events or changes occur which might impair the recovery of recorded amounts. For purposes of the annual goodwill impairment assessment for fiscal years 2026 and 2025, the Company identified two no
Intangible assets consisted of the following as of:
| in thousands | September 30, 2026 | June 30, 2026 | |||||||||
| Definite-lived intangible assets | $ | $ | |||||||||
| Indefinite-lived intangible assets | |||||||||||
| Total intangible assets | |||||||||||
| Accumulated amortization | ( | ( | |||||||||
| Balance as of end of period | $ | $ | |||||||||
Intangible assets consist primarily of customer relationships acquired through business acquisitions. The Company recorded amortization expense of $0.2
Note 7: Leases
The following table presents the components of the Company's right-of-use assets and their classification in the Company's condensed consolidated balance sheets as of:
| Component of Lease Balances | Balance Sheet Line Items | September 30, 2026 | June 30, 2026 | |||||||||||
| in thousands | ||||||||||||||
| Assets: | ||||||||||||||
| Operating lease assets | Operating lease assets | $ | $ | |||||||||||
| Finance lease assets | ||||||||||||||
| Total leased assets | $ | $ | ||||||||||||
15
The following table presents the components of the Company's lease cost and the classification of such costs in the Company's condensed consolidated statements of operations for the three months ended September 30:
| Three Months Ended September 30, | ||||||||||||||||||||||||||
| Component of Lease Cost | Statements of Operations Line Items | 2026 | 2025 | |||||||||||||||||||||||
| in thousands | ||||||||||||||||||||||||||
| Operating lease cost | Cost of care excluding depreciation and amortization and Corporate, general and administrative | $ | $ | |||||||||||||||||||||||
| Finance lease expense: | ||||||||||||||||||||||||||
| Amortization of leased assets | Depreciation and amortization | |||||||||||||||||||||||||
| Interest on lease liabilities | Interest expense, net | |||||||||||||||||||||||||
| Variable lease cost | Cost of care excluding depreciation and amortization and Corporate, general and administrative | |||||||||||||||||||||||||
| Short-term lease cost | Cost of care excluding depreciation and amortization and Corporate, general and administrative | |||||||||||||||||||||||||
| Total lease expense | $ | $ | ||||||||||||||||||||||||
The following table includes the future maturities of lease payments for operating leases and finance leases for periods subsequent to September 30, 2026:
| in thousands | Operating Lease | Finance Lease | Total | ||||||||||||||
| Amount remaining in 2027 | $ | $ | $ | ||||||||||||||
| 2028 | |||||||||||||||||
| 2029 | |||||||||||||||||
| 2030 | |||||||||||||||||
| 2031 | |||||||||||||||||
| Thereafter | |||||||||||||||||
| Total lease payments | |||||||||||||||||
| Less liability accretion / imputed interest | ( | ( | ( | ||||||||||||||
| Total lease liabilities | |||||||||||||||||
| Less: Current lease liabilities | |||||||||||||||||
| Total long-term lease liabilities | $ | $ | $ | ||||||||||||||
Note 8. Long-Term Debt
Long-term debt consisted of the following at September 30, 2026 and June 30, 2026:
| September 30, 2026 | June 30, 2026 | ||||||||||
| in thousands | |||||||||||
| Senior secured borrowings: | |||||||||||
| Term Loan Facility | $ | $ | |||||||||
| Total debt | |||||||||||
| Less: unamortized debt issuance costs | |||||||||||
| Less: current maturities | |||||||||||
| Noncurrent maturities | $ | $ | |||||||||
16
Credit Agreement
The Company is party to a Credit Agreement, dated March 8, 2021, as amended on June 14, 2023 and further amended on August 8, 2025 (as amended, the “Credit Agreement”). The Credit Agreement includes a Term Loan Facility with a $50.7 million term loan (the "Term Loan A Facility"), and a Revolving Credit Facility for maximum borrowing capacity of $100.0 million (the “Revolving Credit Facility”). The maturity date of both the Term Loan A Facility and the Revolving Credit Facility is March 8, 2026.
Terms of the Credit Agreement
Borrowing capacity under the Revolving Credit Facility is subject to (i) any issued amounts under the Company's letters of credit, which as of September 30, 2026 was $7.2 million, and (ii) applicable covenant compliance restrictions and any other conditions precedent to borrowing. Loans under the Credit Agreement are secured by substantially all of the Company’s assets. Principal on the Term Loan A Facility is paid each calendar quarter in an amount equal to 1.25 % of the initial term loan on closing date.
Outstanding principal amounts under the Credit Agreement accrue interest at a variable interest rate. As of September 30, 2026, the interest rate on the Term Loan Facility was 6.31 %. Under the terms of the Credit Agreement, the Revolving Credit Facility fee accrues at 0.50 % of the average daily unused amount and is paid quarterly. As of September 30, 2026, the Company had no borrowings outstanding, $7.2 million of letters of credit issued, and $92.8 million of remaining capacity under the Revolving Credit Facility.
The Credit Agreement requires the Company to meet certain operational and reporting requirements, including, but not limited to, a secured net leverage ratio. Additionally, annual capital expenditures and permitted investments, including acquisitions, are limited to amounts specified in the Credit Agreement. The Credit Agreement also provides certain restrictions on dividend payments and other equity transactions and requires the Company to make prepayments under specified circumstances. As of September 30, 2026, the Company was in compliance with the covenants of the Credit Agreement.
Deferred financing costs are amortized over the term of the underlying debt and unamortized amounts related to the Term Loan A Facility have been partially offset against long-term debt and unamortized amounts related to the Revolving Credit Facility are recorded in deposits and other in the condensed consolidated balance sheets. Total amortization of deferred financing costs was $0.2
Note 9: Commitments and Contingencies
Professional Liability
The Company pays fixed premiums for annual professional liability insurance coverage under a claims-made policy. Under such policy, only claims made and reported to the insurer are covered during the policy term, regardless of when the incident giving rise to the claim occurred. The Company records claim liabilities and expected recoveries, if any, at gross amounts. The Company is not currently aware of any unasserted claims or unreported incidents that are expected to exceed medical malpractice insurance coverage limits.
Litigation
From time to time, the Company is involved in various legal proceedings and subject to claims. The Company regularly evaluates the status of claims and legal proceedings in which it is involved in order to assess whether a loss is probable or there is a reasonable possibility that a loss may have been incurred, and to determine whether accruals are appropriate. The Company expenses legal costs as such costs are incurred.
Civil Investigative Demands
In July 2021, the Company received a civil investigative demand from the Attorney General for the State of Colorado under the Colorado Medicaid False Claims Act. The demand requested information and documents regarding Medicaid billing, patient services and referrals in connection with the Company’s PACE program in Colorado.
17
In February 2022, the Company received a civil investigative demand from the Department of Justice (“DOJ”) under the Federal False Claims Act on similar subject matter. The demand requested information and documents regarding audits, billing, orders tracking, and quality and timeliness of patient services in connection with the Company’s PACE programs in the states where the Company operated as of 2022 (California, Colorado, New Mexico, Pennsylvania, and Virginia). In December 2022 and December 2025, the Company received supplemental civil investigative demands requesting supplemental information on the same matters.
In October 2026, the Company and the United States, acting through the DOJ, and, separately, the States of California, Colorado, New Mexico and Virginia executed settlement agreements relating to the 2021 and 2022 civil investigative demands described above. The agreements required aggregate monetary payments by the Company of approximately $36.9 million made at the end of October, and provide for the release of certain civil and administrative monetary claims arising from the conduct covered by the agreements.
Stockholder Lawsuit
On April 20, 2022, the Board received a books and records demand pursuant to Section 220 of the Delaware General Corporation Law from a purported stockholder of the Company, Brian Hall. On May 15, 2023, Mr. Hall filed a lawsuit in the Delaware Court of Chancery asserting derivative claims for breach of fiduciary duty against certain of the Company’s current and former officers and directors generally relating to alleged failures by the defendants to take remedial actions to address the matters that resulted in sanctions by CMS at certain of the Company’s centers, and alleged misstatements in the Company’s public filings relating to those matters. On May 4, 2026, the parties entered into a settlement agreement to resolve the action. The settlement agreement provided for, among other things, a monetary payment to the Company and an award of plaintiff's attorneys’ fees, to be fully funded by insurance proceeds, as well as the adoption by the Company of certain corporate governance enhancements. The agreement was subject to court approval. On October 7, 2026, at an approval hearing, the Court denied the approval of the proposed settlement because, among other reasons, the Court did not believe that the plaintiff had demonstrated standing to pursue certain of the claims asserted in his complaint. On October 21, 2026, the Company and individual defendants provided to the plaintiff a notice of intent to terminate the settlement agreement. The plaintiff has not responded. The plaintiff could challenge the termination and continue to pursue approval of the settlement agreement, or accept the termination and either dismiss the lawsuit or proceed with litigating the case. At this time, the Company cannot predict when or how the plaintiff will decide to proceed, and is unable to estimate the range of possible losses, if any, from this matter if the plaintiff decides to litigate. The Court has not established any further deadlines in the case.
Litigation Accrual
As of September 30, 2026, the accrual for litigation matters was approximately $36.7 million, substantially all of which related to the 2021 and 2022 civil investigative demands described above. The accrual is included in accounts payable and accrued expenses in the Company's condensed consolidated balance sheet.
Note 10: Income Taxes
The Company recorded an income tax (benefit) expense of $(0.8 ) million and $0.2 million for the three months ended September 30, 2026 and 2025, respectively. This represents an effective tax rate of (4.2 )% and 3.1 % for the three months ended September 30, 2026 and 2025, respectively.
The effective rate for the three months ended September 30, 2026 was different from the federal statutory rate primarily due to the Company’s book income offset partially by disallowed officers’ compensation under Section 162(m) of the Internal Revenue Code (“IRC”), disallowed stock options related to the profit interest units, exclusion of income and losses from entities not subject to tax, lobbying expenses, and the decrease in the Company's valuation allowance against net operating losses which occurred during the three month periods ended September 30, 2026.
18
The Company assesses the valuation allowance recorded against deferred tax assets at each reporting date. The determination of whether a valuation allowance for deferred tax assets is appropriate requires the evaluation of positive and negative evidence that can be objectively verified. Consideration must be given to all sources of taxable income available to realize deferred tax assets, including, as applicable, the future reversal of existing temporary differences, future taxable income forecasts exclusive of the reversal of temporary differences and carryforwards, taxable income in carryback years and tax planning strategies. In estimating income taxes, the Company assesses the relative merits and risks of the appropriate income tax treatment of transactions taking into account statutory, judicial, and regulatory guidance. As of September 30, 2026, the Company determined that it is not “more likely than not” that the deferred tax assets associated with certain state net operating losses will be realized and as such continues to maintain a valuation allowance against these state deferred tax assets. The Company also determined it is "more likely than not" that the deferred tax assets associated with certain federal and combined state net operating losses will be realized and as such has released a valuation allowance against these federal deferred tax assets. The Company has provided $7.5 million at September 30, 2026 and $22.4 million at June 30, 2026, as a valuation allowance against its deferred tax assets for federal and state net operating losses where there is not sufficient positive evidence to substantiate that these deferred tax assets will be realized at a more-likely-than-not level of assurance.
Note 11: Earnings per Share
Basic earnings per share (“EPS”) is computed using the weighted-average number of common shares outstanding during the period. Diluted EPS is computed using the weighted-average number of common shares outstanding during the period, plus the dilutive effect of outstanding options and other equity awards, using the treasury stock method and the average market price of the Company’s common stock during the applicable period. When a loss from continuing operations exists, all dilutive securities and potentially dilutive securities are anti-dilutive and are therefore excluded from the computation of diluted EPS. When net income from continuing operations exists, performance-based units are omitted from the calculation of diluted EPS until it is determined that the performance criteria has been met at the end of the reporting period. For the three months ended September 30, 2026 and 2025, there were 1,035,066 and 258,767 shares, respectively, excluded from the calculation of diluted EPS as they have performance criteria that have not been met at the end of the reporting period.
The following table sets forth the computation of basic and diluted net loss per common share:
| Three months ended September 30, | |||||||||||||||||||||||
| in thousands, except share values | 2026 | 2025 | |||||||||||||||||||||
| Net income attributable to InnovAge Holding Corp. | $ | $ | |||||||||||||||||||||
| Weighted average common shares outstanding (basic) | |||||||||||||||||||||||
| EPS (basic) | $ | $ | |||||||||||||||||||||
| Dilutive shares | |||||||||||||||||||||||
| Weighted average common shares outstanding (diluted) | |||||||||||||||||||||||
| EPS (diluted) | $ | $ | |||||||||||||||||||||
Note 12: Segment Reporting
As of September 30, 2026, the Company had two operating segments, both of which are related to the Company’s PACE offering. The operating segments are based on two geographic divisions, which are East and West. Due to the similar economic characteristics, nature of services, and customers, the Company has aggregated its East and West operating segments into one reportable segment for PACE. Previously, the Company had three operating segments, with the Company’s third remaining operating segment primarily relating to Senior Housing, which was an immaterial operating segment, and shown below as "Other" along with certain corporate unallocated expenses. As of September 2025, the Company no longer operated Senior Housing as the remaining Senior Housing assets were sold.
The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM uses Center-Level Contribution Margin as the measure for assessing performance of its operating segments and allocating resources, predominantly in the annual budget and forecasting process. The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. The CODM considers forecast-to-actual Center-Level Contribution Margin variances on a monthly basis
19
when making decisions about allocating capital and personnel to the segments. Center-Level Contribution Margin is defined as total segment revenues less external provider costs and cost of care (excluding depreciation and amortization).
The Company does not review assets by segment and therefore assets by segment are not disclosed below. For the periods presented, all of the Company’s long-lived assets were located in the United States and all revenue was earned in the United States.
The following table summarizes the operating results regularly provided to the CODM by segment for the three months ended September 30, 2026 and 2025:
| Three months ended September 30, 2026 | Three months ended September 30, 2025 | ||||||||||||||||||||||||||||||||||
| (In thousands) | PACE | All other(a) | Totals | PACE | All other(a) | Totals | |||||||||||||||||||||||||||||
| Capitation revenue | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
| Other service revenue | |||||||||||||||||||||||||||||||||||
| Total revenues | |||||||||||||||||||||||||||||||||||
| External provider costs | |||||||||||||||||||||||||||||||||||
| Cost of care, excluding depreciation and amortization | |||||||||||||||||||||||||||||||||||
| Center-Level Contribution Margin | |||||||||||||||||||||||||||||||||||
| Sales and marketing | |||||||||||||||||||||||||||||||||||
| Corporate, general and administrative | |||||||||||||||||||||||||||||||||||
| Depreciation and amortization | |||||||||||||||||||||||||||||||||||
Loss on assets held for sale | |||||||||||||||||||||||||||||||||||
Operating income | |||||||||||||||||||||||||||||||||||
| Other expense | ( | ( | |||||||||||||||||||||||||||||||||
| Income Before Income Taxes | $ | $ | |||||||||||||||||||||||||||||||||
| Depreciation and amortization | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
_________________________________
Note 13: Related Party Transactions
Secondary Offering
On September 22, 2026, TCO Group Holdings, L.P., the Company's controlling shareholder (the "Selling Shareholder"), sold 10,000,000 shares of the Company's common stock in an underwritten public offering at a price of $9.25 per share. On October 20, 2026, the underwriters exercised in full their option to purchase an additional 1,500,000 shares from the Selling Shareholder at the same price. The Company did not sell any shares in the offering and did not receive any proceeds. Pursuant to its obligations under the Registration Rights Agreement, of which the Company is a party, the Company paid the offering expenses of $1.7 million.
The Shares were registered under the Securities Act pursuant to the Company's shelf Registration Statement on Form S-3 filed on July 31, 2026.
20
Note 14: Subsequent Events
The Company has evaluated subsequent events through November 3, 2026, the date on which the condensed consolidated financial statements were issued and noted there were none, except as disclosed in Note 9, "Commitments and Contingencies."
21
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly due to numerous known and unknown risks and uncertainties, including those discussed below and in the section entitled “Cautionary Note on Forward-Looking Statements.” Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section titled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026 (“2026 10-K”).
Overview
InnovAge Holding Corp. (“InnovAge”) became a public company in March 2021. As of September 30, 2026, the Company served approximately 8,420 PACE participants, and operated 20 PACE centers across six states: California, Colorado, Florida, New Mexico, Pennsylvania, and Virginia. At the beginning of fiscal year 2027, to increase operational efficiency, we began the process of converting two legacy PACE centers to alternate care setting (“ACS”) centers in Pennsylvania. Once the process is complete, which we expect to be during the second fiscal quarter, these ACS centers will provide our participants with flexibility to participate in activities and receive certain services.
Trends and Uncertainties Affecting the Company
Increased cost of care and external provider costs. We anticipate increased cost from our third-party service providers beginning in the second half of fiscal year 2027, or the first half of calendar year 2027, as providers seek to offset heightened expenses resulting, in part, from budget pressures associated with the Reconciliation Act, budget cuts to providers from state Medicaid programs, as well as possible increases in other costs in order to provide healthcare services. We did not experience a material increase to our cost of care and external provider costs during the first quarter of fiscal year 2027 and do not anticipate a material increase in the second quarter. However, we continue to monitor the situation, including with respect to the second half of fiscal year 2027. We continue to believe that our ongoing clinical and operational value initiatives may assist us in reducing unnecessary utilization and offsetting the increased costs anticipated in the later part of fiscal year 2027.
Labor market. The healthcare sector continues to experience workforce shortages, particularly in geriatrics, primary care and direct care roles, as well as a complex set of challenges in hiring additional professionals, which continued through the first quarter of fiscal year 2027. Competition from health systems and home health providers, drivers and caregivers has remained challenging for the Company’s ability to recruit and retain staff. Labor market pressures and competition continues to impact wage and benefit costs for our direct care providers and have also affected our staffing ability, which could impact our enrollment capacity. To mitigate these challenges, we continue to review our compensation and benefits to align with the markets in which we operate and focus our retention programs on critical roles and our operational measures to help improve productivity and continue reducing reliance on agency staffing. Partially as a result of increased competition and other market trends, there was an increase in the cost of care for the first quarter of fiscal year 2027 compared to the comparable period for fiscal year 2026, as discussed in "Results of Operations" below.
Census and capitation revenue. We continued to monitor the delays and increased gaps in eligibility, both for new enrollments and Medicaid redetermination applications, during the first quarter of fiscal year 2027. Such delays and eligibility gaps stem from issues with state enrollment and redetermination processes which vary by state and county. While processing delays abated modestly during fiscal year 2026, it is possible that these delays could persist or be exacerbated due to potential impacts of the Reconciliation Act. The foregoing has not yet had a material effect on the Company’s financial statements or operations; however, we continue to monitor the situation.
Medicaid Spending and Rates. Among other things, the Reconciliation Act has constrained states' use of provider taxes to finance Medicaid programs and some states have mandated changes in order to reduce Medicaid spending. Consequent state budgetary pressures may lead to (i) reductions in state workforce, which may include those responsible for overseeing PACE, possibly causing delays in eligibility determinations and discharge of other state responsibilities; (ii) reduction or removal of optional Medicaid services from the PACE benefit package; and (iii) pressure on Medicaid capitation rates. In Colorado, where we serve the largest cohort of our PACE census, we anticipate a decrease in Medicaid premium rates,
22
which will be retroactive for the fiscal year beginning July 1, 2026. We also expect to face Medicaid reimbursement wage pressures from other states that release rates effective January 1, 2027, such as California, which could impact the latter half of our fiscal year. As a result, while we have not experienced any material impacts during the first quarter, we continue to expect the rate pressures to impact the Company's margins in fiscal 2027 and continue to monitor the full effects of the Reconciliation Act on the Company.
State Moratoriums. The California Department of Health Care Services ("DHCS") and, effective October 31, 2026, the Colorado Department of Health Care Policy & Financing have each paused PACE applications for all new PACE organizations and service area expansions until at least November 19, 2027 and October 31, 2028, respectively, or until otherwise notified. The pause in California does not apply to the ongoing Bakersfield center application, the review of which may resume following remediation of the deficiencies raised in our Sacramento and San Bernardino centers and the completion of the San Bernardino medical review. If other states enact similar moratoriums or restrictions on PACE expansion, our growth strategies or opportunities could be reduced or delayed.
For additional information on the various risks posed by macroeconomic events, regulation, and employee matters, please see the section entitled “Risk Factors” included in Part I, Item 1A of our 2026 10-K.
Key Factors Affecting Our Performance
Our historical financial performance has been, and we expect our financial performance in the future to be, driven by the following factors:
•Our participants. We focus on providing all-inclusive care to frail, high-cost, dual-eligible seniors. We directly contract with government payors, such as Medicare and Medicaid, through PACE and receive a capitated risk-adjusted payment to manage the totality of a participant’s medical care across all settings. InnovAge manages participants that are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in Medicare Advantage (“MA”) programs. As a result, we receive larger payments for our participants compared to MA participants. This is driven by two factors: (i) we believe we manage a higher acuity population, with an average risk adjustment factor (“RAF”) score of 2.51 based on InnovAge data as of September 30, 2026, compared to a baseline 1.0 RAF score calculated by CMS annually to represent the average Medicare fee-for-service beneficiary, with a higher RAF score indicating poorer health and higher predicted healthcare costs; and (ii) we have Medicaid spend in addition to Medicare. Our participants are managed on a capitated, or at-risk basis, where InnovAge is financially responsible for all participant medical costs. Our comprehensive care model and globally capitated payments are designed to cover participants from enrollment until the end of life, including coverage for participants requiring hospice and palliative care. For dual-eligible participants, we receive PMPM payments directly from Medicare and Medicaid, which provides recurring revenue streams and significant visibility into our revenue. The Medicare portion of our capitated payment is risk-based on the underlying medical conditions and frailty of each participant. We continue to strengthen our encounter data submission process so that our revenue more accurately reflects the acuity of the populations we serve.
•Our ability to grow enrollment and capacity within existing centers. We believe all seniors should have access to the type of all-inclusive care offered by the PACE model. Several factors can affect our ability to grow enrollment and capacity within existing centers, including competition, costs and regulatory compliance.
•Our ability to maintain high participant satisfaction and retention. Our comprehensive individualized care model and frequency of interaction with participants generates high levels of participant satisfaction. Our average participant tenure was 3.1 years as of September 30, 2026, measured as tenure from enrollment to disenrollment, among our centers that have been operated by us for at least five years. Furthermore, we experience low levels of voluntary disenrollment, averaging 6.5% annually over the last three fiscal years.
•Effectively managing costs. We receive capitated payments to manage the totality of a participant’s medical care across all settings. The risk pool of our population is highly acute. Various factors, including increased salaries, wages and benefits, increased staffing, annual increases in assisted living and nursing facility unit cost and general medical inflation have affected our external provider costs and cost of care, excluding depreciation and amortization, which represented approximately 76% of our revenue in the three months ended September 30, 2026.
23
•Center-level Contribution Margin. The Company's management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. As we serve more participants in existing centers, we expect to leverage our fixed cost base at those centers and increase the value of a center to our business over time.
•Our ability to expand via de novo centers within existing and new markets. Several factors can affect our ability to open de novo centers, including competition, costs and actions by local and state regulators, such as the moratorium issued in California by DHCS and any sanctions issued by regulators, legal, community or other obstacles in the construction or opening of such centers.
In response to an audit to our Sacramento center and a medical review of our San Bernardino center, which have been previously disclosed, DHCS suspended its attestations in support of the planned de novo centers in Downey and Bakersfield, California. CMS has closed its process. DHCS closed its audit with respect to the Sacramento audit, but its medical review with respect to the San Bernardino center is ongoing. On December 23, 2025, we received a formal Corrective Action Plan (CAP) from DHCS to remediate findings resulting from the San Bernardino medical review. We continue working closely with the State to fulfill the obligations under the CAP. In July 2026, we withdrew our PACE application for the previously planned Downey center, however, we continue to pursue the PACE application for the de novo center in Bakersfield. DHCS provided notice that they would consider restoring the State Attestation that would allow us to open our Bakersfield center based upon the successful remediation of the deficiencies raised in our Sacramento and San Bernardino centers and its completion of the medical review.
•Execute tuck-in acquisitions, strategic transactions and partnerships. Since fiscal year 2019, we have acquired and integrated several PACE organizations. We also have pursued and intend to continue pursuing additional relationships with key stakeholders, existing organizations and other care providers in order to form partnerships in target geographies.
•Our ability to maintain high quality of regulatory compliance. The Company's priority is to continue to maintain high quality of regulatory compliance in all its centers.
•Contracting with government payors. Our economic model relies on our capitated arrangements with government payors, namely Medicare and Medicaid. We view the government not only as a payor but also as a key partner in our efforts to expand into new geographies and access more participants in our existing markets. Maintaining, supporting and growing these relationships, in existing markets as well as new geographies, is critical to our long-term success.
•Investing to support growth. We intend to continue investing in our centers, value-based care model, and sales and marketing initiatives to support long-term growth. We expect our expenses to increase in absolute dollars for the foreseeable future to support our growth and as the result of current and potential legal and regulatory proceedings. We plan to continue investing in our growth while also maintaining focus on managing our results of operations. During fiscal years 2025 and 2026 we made investments to increase our sophistication as a payor to drive clinical value, improve outcomes, and manage cost trends, and have continued investing in these areas, including more recently in technology and artificial intelligence capabilities, into fiscal year 2027. Accordingly, in the short term, these activities increase our expenses as a percentage of revenue. While many of the anticipated benefits are expected to be realized over time, we believe certain benefits from these investment are beginning to emerge, and we expect these investments to positively impact our business and results of operations over the longer term.
•Seasonality of our business. Our operational and financial results, including medical costs and per-participant revenue risk adjustment reconciliation payments, will experience some variability depending upon the time of year in which they are measured. Medical costs vary most significantly as a result of (i) the weather, with certain illnesses, such as the influenza virus, COVID-19 and respiratory syncytial viruses, being more prevalent during colder months of the year, which generally increases per-participant costs and (ii) the number of business days in a period, with shorter periods generally having lower medical costs all else equal. Per-participant risk adjustment reconciliation revenue represent the difference between our estimate of per-participant capitation revenue to be received and actual revenue received from CMS, which is based on CMS’s determination of a participant’s RAF score as measured twice per year and is based on the evolving acuity of a participant. Where there is a difference between our estimate and the final determination from
24
CMS, we may record either an increase or decrease in risk score reconciliation revenue. Historically, these risk adjustment reconciliation payments typically occur between June and July, but the timing of these payments is determined by CMS, and we have neither visibility into nor control over the timing of such payments. The variability of participant enrollments and voluntary disenrollments has also been impacted by additional offerings by MA, special needs programs and other competitors including PACE organizations in select markets.
Components of Results of Operations
Revenue
Capitation Revenue. In order to provide comprehensive services to manage the totality of a participant’s medical care across all settings, we receive fixed or capitated fees per participant that are paid monthly by Medicare, Medicaid, Veterans Affairs (“VA”) and private pay sources.
Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. The PACE state contracts between us and the respective state Medicaid administering agency are renewed annually each June 30 in all states other than California and Pennsylvania, which contract on a calendar-year basis. We are currently operating in good standing under each of our PACE state contracts. For a discussion of our revenue recognition policies, please see Critical Accounting Estimates below and Note 2 “Summary of Significant Accounting Policies” to our consolidated financial statements included in our 2026 10-K.
Other Service Revenue. Other service revenue primarily consists of revenues derived from state grants. For a discussion of our revenue recognition policies, please see Critical Accounting Estimates below and Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our 2026 10-K.
Operating Expenses
External Provider Costs. External provider costs consist primarily of the costs for medical care provided by non-InnovAge providers. We separate external provider costs into four categories: inpatient (e.g., hospital), housing (e.g., assisted living and skilled nursing facility), outpatient and pharmacy. In aggregate, external provider costs represent the largest portion of our expenses.
Cost of Care, Excluding Depreciation and Amortization. Cost of care, excluding depreciation and amortization, includes the costs we incur to operate our care delivery model. This includes costs related to salaries, wages and benefits for our Interdisciplinary Care Teams ("IDTs") and other center-level staff, participant transportation, medical supplies, occupancy, insurance and other operating costs. IDT employees include medical doctors, registered nurses, social workers, physical, occupational, and speech therapists, nursing assistants, and transportation workers. Other center-level employees include clinic managers, dieticians, activity assistants and certified nursing assistants. Cost of care excludes any expenses associated with sales and marketing activities incurred at a local level as well as any allocation of our corporate, general and administrative expenses. A portion of our cost of care, including our employee-related costs, is directly related to the number of participants cared for in a center. The remainder of our cost of care is fixed relative to the number of participants we serve, such as occupancy and insurance expenses. When we open new centers, we expect cost of care, excluding depreciation and amortization, to increase in absolute dollars due to higher census and facility related costs.
Sales and Marketing. Sales and marketing expenses consist of employee-related expenses, including salaries, commissions, and employee benefits costs, for all employees engaged in marketing, sales, community outreach and sales support as well as financial eligibility support for both prospective and existing participants. These employee-related expenses capture all costs for both our field-based and corporate sales and marketing teams. Sales and marketing expenses also include local and centralized advertising costs, as well as the infrastructure required to support our marketing efforts. We expect these costs to increase in absolute dollars over time as we continue to grow our participant census. We evaluate our sales and marketing expenses relative to our participant growth and will invest more heavily in sales and marketing from time-to-time to the extent we believe such investment can accelerate our growth without negatively affecting profitability.
Corporate, General and Administrative Expenses. Corporate, general and administrative expenses consist primarily of employee-related costs, including salaries, benefits and other compensation, as well as costs associated with technology, occupancy, professional services, insurance and other corporate functions. We expect our corporate, general and
25
administrative expenses to increase in absolute dollars as we continue to invest in the infrastructure and resources necessary to support operations, growth, and to comply with the requirement of being a public company. However, over the long term, we anticipate corporate, general and administrative expenses to decrease as a percentage of revenue as we gain operating leverage, although such expenses may fluctuate as a percentage of revenue from period to period due to the timing and amount of these expenses.
Depreciation and Amortization. Depreciation and amortization expenses are primarily attributable to our buildings and leasehold improvements and our equipment and vehicles. Depreciation and amortization are recorded using the straight-line method over the shorter of estimated useful life or lease terms, to the extent the assets are being leased.
For more information relating to the components of our results of operations, see Results of Operations below and Note 2 “Summary of Significant Accounting Policies” to our consolidated financial statements included in our 2026 10-K.
Results of Operations
The following table sets forth our condensed consolidated results of operations for the periods presented:
| Three Months Ended September 30, | |||||||||||||||||||||||
| in thousands | 2026 | 2025 | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Capitation revenue | $ | 264,690 | $ | 235,751 | |||||||||||||||||||
| Other service revenue | 67 | 354 | |||||||||||||||||||||
| Total revenues | 264,757 | 236,105 | |||||||||||||||||||||
| Expenses | |||||||||||||||||||||||
| External provider costs | 115,671 | 108,863 | |||||||||||||||||||||
| Cost of care, excluding depreciation and amortization | 85,499 | 75,886 | |||||||||||||||||||||
| Sales and marketing | 8,630 | 7,605 | |||||||||||||||||||||
| Corporate, general and administrative | 29,149 | 30,273 | |||||||||||||||||||||
| Depreciation and amortization | 5,658 | 5,085 | |||||||||||||||||||||
| Loss on assets held for sale | — | 104 | |||||||||||||||||||||
| Total expenses | 244,607 | 227,816 | |||||||||||||||||||||
| Operating Income | 20,150 | 8,289 | |||||||||||||||||||||
| Other Income (Expense) | |||||||||||||||||||||||
| Interest expense, net | (123) | (1,251) | |||||||||||||||||||||
Other income, net | 10 | 878 | |||||||||||||||||||||
| Total other expense | (113) | (373) | |||||||||||||||||||||
| Income Before Income Taxes | 20,037 | 7,916 | |||||||||||||||||||||
| Provision (Benefit) for Income Taxes | (841) | 247 | |||||||||||||||||||||
| Net Income | 20,878 | 7,669 | |||||||||||||||||||||
| Less: net income (loss) attributable to noncontrolling interests | 1,325 | (350) | |||||||||||||||||||||
| Net Income Attributable to InnovAge Holding Corp. | $ | 19,553 | $ | 8,019 | |||||||||||||||||||
Revenues
| Three Months Ended September 30, | Change | ||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | $ | % | ||||||||||||||||||||||||||||||||||||||||||||
| in thousands | |||||||||||||||||||||||||||||||||||||||||||||||
| Capitation revenue | $ | 264,690 | $ | 235,751 | $ | 28,939 | 12.3 | % | |||||||||||||||||||||||||||||||||||||||
| Other service revenue | 67 | 354 | (287) | (81.1) | % | ||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 264,757 | $ | 236,105 | $ | 28,652 | 12.1 | % | |||||||||||||||||||||||||||||||||||||||
26
Capitation revenue. Capitation revenue was $264.7 million for the three months ended September 30, 2026, an increase of $28.9 million, or 12.3%, compared to $235.8 million for the three months ended September 30, 2025. This increase was driven by a $13.2 million, or 5.3%, increase in capitation rates coupled with a $15.7 million, or 6.7%, increase in member months for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025. The increase in capitation rates for the three months ended September 30, 2026 was primarily driven by (i) a 4.7% increase in Medicaid capitation rates as determined by the States and (ii) a 5.8% increase in Medicare capitation rates. The increase in member months was primarily due to growth in our California, Colorado and Florida centers.
Operating Expenses
| Three Months Ended September 30, | Change | ||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | $ | % | ||||||||||||||||||||||||||||||||||||||||||||
| in thousands | |||||||||||||||||||||||||||||||||||||||||||||||
| External provider costs | $ | 115,671 | $ | 108,863 | $ | 6,808 | 6.3% | ||||||||||||||||||||||||||||||||||||||||
| Cost of care (excluding depreciation and amortization) | 85,499 | 75,886 | 9,613 | 12.7% | |||||||||||||||||||||||||||||||||||||||||||
| Sales and marketing | 8,630 | 7,605 | 1,025 | 13.5 | % | ||||||||||||||||||||||||||||||||||||||||||
| Corporate, general, and administrative | 29,149 | 30,273 | (1,124) | (3.7)% | |||||||||||||||||||||||||||||||||||||||||||
| Depreciation and amortization | 5,658 | 5,085 | 573 | 11.3% | |||||||||||||||||||||||||||||||||||||||||||
| Loss on assets held for sale | — | 104 | (104) | —% | |||||||||||||||||||||||||||||||||||||||||||
| Total operating expenses | $ | 244,607 | $ | 227,816 | $ | 16,791 | |||||||||||||||||||||||||||||||||||||||||
External provider costs. External provider costs were $115.7 million for the three months ended September 30, 2026, an increase of $6.8 million, or 6.3%, compared to $108.9 million for the three months ended September 30, 2025. The increase was driven by an increase of $7.3 million, or 6.7%, in member months partially offset by a decrease of $0.5 million, or 0.4%, in cost per participant for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025. The decrease in cost per participant for the three months ended September 30, 2026 was primarily driven by a decrease in assisted living and permanent nursing facility utilization and a decrease in pharmacy expense. The decrease in cost per participant was partially offset by an increase in inpatient utilization and an increase in assisted living and nursing facility unit cost.
Cost of care (excluding depreciation and amortization). Cost of care (excluding depreciation and amortization) expense was $85.5 million for the three months ended September 30, 2026, an increase of $9.6 million, or 12.7%, compared to $75.9 million for the three months ended September 30, 2025. This increase was driven by an increase of $4.5 million, or 5.6%, in cost per participant coupled with an increase of $5.1 million, or 6.7%, in member months. The overall increase of cost of care (excluding depreciation and amortization) expense for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025 was primarily driven by (i) a $3.5 million net increase in salaries, wages and benefits due primarily to an increase in headcount, higher wage rates, and cost associated with organizational restructure (ii) $1.4 million in third party fees associated with pharmacy services, (iii) $1.4 million in contract provider services, (iv) $1.9 million in fleet costs including contract transportation, and (v) $1.1 million in supplies and administrative costs.
Sales and marketing. Sales and marketing expenses were $8.6 million for the three months ended September 30, 2026, an increase of $1.0 million, or 13.5%, compared to $7.6 million for the three months ended September 30, 2025, primarily due to higher wage rates and increased marketing spend to support growth.
Corporate, general and administrative. Corporate, general and administrative expenses were $29.1 million for the three months ended September 30, 2026, a decrease of $1.1 million, or 3.7%, compared to $30.3 million for the three months ended September 30, 2025. This decrease for the three months ended September 30, 2026 as compared to the three months ended September 30, 2025 was primarily due to a decrease in salaries, wages and benefits associated with lower headcount.
Loss on assets held for sale. On September 11, 2025, the Company closed on the sale of assets previously held for sale and recorded an additional loss on assets held for sale of $0.1 million for the three months ended September 30, 2025.
27
Other Income (Expense)
| Three Months Ended September 30, | Change | ||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | $ | % | ||||||||||||||||||||||||||||||||||||||||||||
| in thousands | |||||||||||||||||||||||||||||||||||||||||||||||
| Interest expense, net | $ | (123) | $ | (1,251) | $ | 1,128 | (90.2)% | ||||||||||||||||||||||||||||||||||||||||
| Other income, net | 10 | 878 | (868) | (98.9)% | |||||||||||||||||||||||||||||||||||||||||||
| Total other expense | $ | (113) | $ | (373) | $ | 260 | |||||||||||||||||||||||||||||||||||||||||
Interest expense, net. Interest expense, net, consists primarily of interest payments on our outstanding borrowings, net of interest income earned on our cash and cash equivalents and restricted cash. The decrease in interest expense, net was due to a $0.8 million increase in interest income earned and a $0.3 million decrease in interest expense during the three months ended September 30, 2026 as compared to the three months ended September 30, 2025.
Other income, net. Other income, net decreased due to a $0.5 million decrease in investment income and a $0.3 million decrease in gains on disposal of capital assets in the three months ended September 30, 2026 as compared to the three months ended September 30, 2025.
Provision for Income Taxes
The Company and its subsidiaries calculate federal and state income taxes currently payable and for deferred income taxes arising from temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to enacted tax laws and rates applicable to periods in which those temporary differences are expected to be recovered or settled. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment. The members of InnovAge Sacramento, InnovAge Orlando, and InnovAge Tampa had or have, as applicable, elected to be taxed as partnerships, and no provision (benefit) for income taxes for InnovAge Sacramento, InnovAge Orlando, or InnovAge Tampa is included in the condensed consolidated financial statements.
A valuation allowance is provided to the extent that it is more likely than not that deferred tax assets will not be realized. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination based on the technical merits of the position. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and penalty expense associated with uncertain tax positions as a component of provision (benefit) for income taxes.
During the three months ended September 30, 2026 and 2025, we reported an income tax (benefit) expense of $(0.8) million and $0.2 million, respectively. The decrease of $1.0 million for the three months ended September 30, 2026 compared to the three months ended September 30, 2025, was primarily due to (i) our pretax book income recognized during the three months ended September 30, 2026, as compared to pretax book income recognized during the three months ended September 30, 2025, (ii) a discrete item to account for the windfall on vested RSUs, (iii) the change in our valuation allowance, and (iv) a discrete item for the release of valuation allowance on certain state Net Operating Losses.
Key Business Metrics and Non-GAAP Measures
In addition to our GAAP financial information, we review a number of operating and financial metrics, including the following key metrics and non-GAAP measures, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. We believe these metrics provide additional perspective and insights when analyzing our core operating performance from period to period and evaluating trends in historical operating results. These key business metrics and non-GAAP measures should not be considered superior to, or a
28
substitute for, and should be read in conjunction with, the GAAP financial information presented herein. These measures may not be comparable to similarly-titled performance indicators used by other companies.
| Three months ended September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| dollars in thousands | |||||||||||
| Key Business Metrics: | |||||||||||
Centers(a) | 20 | 20 | |||||||||
Census(a)(b) | 8,420 | 7,890 | |||||||||
Total Member Months(a)(b) | 25,070 | 23,500 | |||||||||
Center-level Contribution Margin(c) | $ | 63,587 | $ | 51,356 | |||||||
Center-level Contribution Margin as a % of revenue(c) | 24.0 | % | 21.8 | % | |||||||
| GAAP Measures: | |||||||||||
| Net income | $ | 20,878 | $ | 7,669 | |||||||
| Net income margin | 7.9 | % | 3.2 | % | |||||||
| Non-GAAP Measures: | |||||||||||
Adjusted EBITDA(c) | $ | 31,251 | $ | 17,642 | |||||||
Adjusted EBITDA Margin(c) | 11.8 | % | 7.5 | % | |||||||
________________________
(a)Includes InnovAge Sacramento, InnovAge Orlando and, InnovAge Tampa, which the Company owns and controls through joint ventures and are consolidated in our financial statements.
(b)Amounts are approximate.
(c)Center-level Contribution Margin, Center-level Contribution Margin as a percentage of revenue, Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. For a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the period indicated, see below.
Centers
We define our centers as those centers open for business and attending to participants at the end of a particular period.
Census
Our census is comprised of our capitated participants for whom we are financially responsible for their total healthcare costs.
Total Member Months
We define Total Member Months as the total number of participants multiplied by the number of months within the respective reporting period in which each participant was enrolled in our program. We believe this is a useful metric as it more precisely tracks the number of participants we serve throughout the year.
Center-level Contribution Margin
The Company's management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs. For purposes of evaluating Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing expenses or corporate, general and administrative expenses across our centers. Center-level Contribution Margin was $63.6 million and $51.4 million for the three months ended September 30, 2026 and 2025, respectively. The increase in Center-level Contribution Margin for the three months ended September 30, 2026 compared to the three months ended September 30,
29
2025 was primarily due to a 12.1% increase in total revenue, offset by a 8.9% increase in external provider costs and cost of care, excluding depreciation and amortization, during the same period. For more information relating to Center-level Contribution Margin, see Note 12 “Segment Reporting” to our condensed consolidated financial statements. A reconciliation of Center-level Contribution Margin to loss before income taxes, the most directly comparable GAAP measure, for each of the periods is as follows:
| September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||||||||
| (In thousands) | PACE | All other(a) | Totals | PACE | All other(a) | Totals | |||||||||||||||||||||||||||||
| Capitation revenue | $ | 264,690 | $ | — | $ | 264,690 | $ | 235,751 | $ | — | $ | 235,751 | |||||||||||||||||||||||
| Other service revenue | 67 | — | 67 | 97 | 257 | 354 | |||||||||||||||||||||||||||||
| Total revenues | 264,757 | — | 264,757 | 235,848 | 257 | 236,105 | |||||||||||||||||||||||||||||
| External provider costs | 115,671 | — | 115,671 | 108,863 | — | 108,863 | |||||||||||||||||||||||||||||
| Cost of care, excluding depreciation and amortization | 85,499 | — | 85,499 | 75,735 | 151 | 75,886 | |||||||||||||||||||||||||||||
| Center-Level Contribution Margin | 63,587 | — | 63,587 | 51,250 | 106 | 51,356 | |||||||||||||||||||||||||||||
| Sales and marketing | 8,630 | 7,605 | |||||||||||||||||||||||||||||||||
| Corporate, general and administrative | 29,149 | 30,273 | |||||||||||||||||||||||||||||||||
| Depreciation and amortization | 5,658 | 5,085 | |||||||||||||||||||||||||||||||||
Loss on assets held for sale | — | 104 | |||||||||||||||||||||||||||||||||
Operating income | 20,150 | 8,289 | |||||||||||||||||||||||||||||||||
| Other expense | (112) | (373) | |||||||||||||||||||||||||||||||||
Income Before Income Taxes | $ | 20,038 | $ | 7,916 | |||||||||||||||||||||||||||||||
| Depreciation and amortization | $ | 5,658 | $ | — | $ | 5,658 | $ | 5,084 | $ | 1 | $ | 5,085 | |||||||||||||||||||||||
Income Before Income Taxes as a % of revenue | 7.6 | % | 3.4 | % | |||||||||||||||||||||||||||||||
| Center- Level Contribution Margin as a % of revenue | 24.0 | % | 21.8 | % | |||||||||||||||||||||||||||||||
_________________________________
(a)Center-level Contribution Margin from a segment below the quantitative thresholds were primarily attributable to the Senior Housing operating segment of the Company, which senior housing assets were sold on September 11, 2025. This segment never met any of the quantitative thresholds for determining reportable segments.
Adjusted EBITDA and Adjusted EBITDA Margin
We define Adjusted EBITDA as net income (loss) adjusted for interest expense, net, other investment income, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to stock-based compensation, litigation costs and settlements, business optimization, offering expenses, loss on assets held for sale, and gain on sale of assets. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue. For the three months ended September 30, 2026 and 2025, net income was $20.9 million and $7.7 million, respectively, representing a year-over-year increase of 172.2%. For the three months ended September 30, 2026, net income margin was 7.9%, as compared to net income margin of 3.2% for the three months ended September 30, 2025. The increase in Adjusted EBITDA and Adjusted EBITDA margin was primarily due to (i) increased census and (ii) increased capitation rates.
Adjusted EBITDA and Adjusted EBITDA margin are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net income (loss) and net income (loss) margin, respectively, as determined by GAAP. We believe that Adjusted EBITDA
30
and Adjusted EBITDA margin are appropriate measures of operating performance because the metrics eliminate the impact of revenue and expenses that do not relate to our ongoing business performance and certain noncash expenses, allowing us to more effectively evaluate our core operating performance and trends from period to period. We believe that Adjusted EBITDA and Adjusted EBITDA margin help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other GAAP financial measures, including net income (loss) and net income (loss) margin. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA. The use of the term Adjusted EBITDA varies from others in our industry.
A reconciliation of net loss to Adjusted EBITDA, the most directly comparable GAAP measure, for each of the periods is as follows:
| Three months ended September 30, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Net income | $ | 20,878 | $ | 7,669 | |||||||||||||||||||
| Interest expense, net | 123 | 1,251 | |||||||||||||||||||||
Other investment income(a) | (16) | (499) | |||||||||||||||||||||
| Depreciation and amortization | 5,658 | 5,085 | |||||||||||||||||||||
Provision (benefit) for income tax | (841) | 247 | |||||||||||||||||||||
| Stock-based compensation | 1,741 | 2,308 | |||||||||||||||||||||
Litigation costs and settlement(b) | 322 | 979 | |||||||||||||||||||||
Business optimization(c) | 1,707 | 879 | |||||||||||||||||||||
Offering expenses(d) | 1,679 | — | |||||||||||||||||||||
Loss on assets held for sale(e) | — | 104 | |||||||||||||||||||||
Gain on sale of assets(f) | — | (381) | |||||||||||||||||||||
| Adjusted EBITDA | $ | 31,251 | $ | 17,642 | |||||||||||||||||||
________________________
(a)Reflects investment income related to short-term investments included in our condensed consolidated statement of operations.
(b)Reflects charges/(credits) related to litigation by stockholders, civil investigative demands, and settlement with our former pharmacy provider. Refer to Note 9, "Commitments and Contingencies" to our condensed consolidated financial statements included herein and in prior SEC filings for more information. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy.
(c)Reflects charges related to business optimization initiatives. Such charges relate to one-time investments in projects designed to enhance our technology and compliance systems and improve and support the efficiency and effectiveness of our operations. For the three months ended September 30, 2026, this consists of (i) $1.5 million of costs related to organizational restructure and executive severance and (ii) $0.2 million of costs related to the closure of the previously planned de novo center in Downey, California. For the three months ended September 30, 2025, this consists of costs related to organizational restructure and executive severance.
(d)For the three months ended September 30, 2026, reflects costs related to the filing and legal fees incurred in connection with preparation and filing of the Form S-3 Shelf Registration Statement and subsequent secondary offering, pursuant to the Registration Rights Agreement to which the Company is a party.
(e)For the three months ended September 30, 2025, reflects loss related to the Company's sale of its managing member interest in InnovAge Senior Housing Thornton, LLC, the Company's senior housing assets, and the adjacent vacant land.
(f)For the three months ended September 30, 2025, reflects gain on sale of center equipment that was purchased for the previously planned de novo center in Louisville, Kentucky
31
Liquidity and Capital Resources
General
We have financed our operations principally through cash flows from operations and through borrowings under our credit facilities. As of September 30, 2026, we had cash and cash equivalents of $119.3 million, an increase of $21.4 million from June 30, 2026, and short-term investments of $43.7 million, an increase of $0.3 million from June 30, 2026. The increase in cash and cash equivalents and short-term investments was primarily due to timing of cash receipts for services provided. Our cash and cash equivalents primarily consist of highly liquid investments in demand deposit accounts and cash. Our short-term investments primarily consist of investments in mutual funds.
Our capital resources are generally used to fund (i) debt service requirements, the majority of which relate to the quarterly principal payments of the Term Loan A Facility (as defined below) due August 2028, (ii) finance and operating lease obligations, which are generally paid on a monthly basis and expire on various terms from calendar year 2026 through 2039, (iii) the operations of our business, (iv) income tax payments, which are generally due on a quarterly and annual basis, (v) capital additions, which include acquisitions and de novo centers, and (vi) share repurchases, if any. We also will continue investing in resources and initiatives to provide necessary and quality services to our participants. Collectively, these obligations are expected to represent a significant liquidity requirement of our Company on both a short-term (next 12 months) and long-term (beyond 12 months) basis. For additional information, see Note 7, “Leases”, Note 8, “Long-Term Debt”, and Note 9, “Commitments and Contingencies” to our condensed consolidated financial statements.
We believe that our cash and cash equivalents and our cash flows from operations, available funds, and access to financing sources, including our Revolving Credit Facility, will be sufficient to fund our operating and capital needs for the next 12 months and beyond. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Our actual results could vary because of, and our future capital requirements will depend on, many factors, including our growth rate, our ability to retain and grow the number of PACE participants, and the expansion of sales and marketing activities and other costs of operating the business. We may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations, and financial condition would be adversely affected.
The Company is party to a Credit Agreement dated March 8, 2021, as amended on June 14, 2023 and further amended on August 8, 2025 (as amended, the "Credit Agreement"), which consists of a $50.7 million term loan (the "Term Loan A Facility") and a revolving credit facility with $100.0 maximum borrowing capacity (the “Revolving Credit Facility”), and a maturity date of August 8, 2028. As of September 30, 2026, we had $48.2 million of debt outstanding under our Term Loan A Facility, and no borrowings outstanding, $7.2 million of letters of credit issued, and $92.8 million of remaining borrowing capacity under the Revolving Credit Facility.
For more information about our debt, see Note 8 “Long-Term Debt” to our condensed consolidated financial statements.
We currently intend to retain substantially all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness. We do not anticipate paying any cash dividends in the foreseeable future.
32
Condensed Consolidated Statements of Cash Flows
Our condensed consolidated statements of cash flows for the three months ended September 30, 2026 and 2025 are summarized as follows:
| Three months ended September 30, | |||||||||||||||||
| 2026 | 2025 | $ Change | |||||||||||||||
| in thousands | |||||||||||||||||
| Net cash provided by operating activities | $ | 28,742 | $ | 3,924 | $ | 24,818 | |||||||||||
| Net cash used in investing activities | (3,425) | (814) | (2,611) | ||||||||||||||
| Net cash used in financing activities | (3,956) | (11) | (3,945) | ||||||||||||||
| Net change in cash, cash equivalents and restricted cash | $ | 21,361 | $ | 3,099 | $ | 18,262 | |||||||||||
Operating Activities. The increase in net cash provided by operating activities for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was driven primarily by $12.8 million increase in net income, net of non-cash adjustments, and a $12.0 million change in operating assets and liabilities driven by a change in accounts payable and accrued expenses.
Investing Activities. The increase in net cash used in investing activities for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was due to $3.7 million in proceeds from a one-time sale of assets in the prior year period, partially offset by a $1.1 million decrease in purchases of property and equipment.
Financing activities. The increase in net cash used in financing activities for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was primarily due to a $3.2 million contribution from our InnovAge Tampa joint venture partner that occurred at the time of closing the transaction.
Critical Accounting Estimates
The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates under different assumptions or conditions, impacting our reported results of operations and financial condition.
Certain accounting estimates involve significant judgments and assumptions by management, which have a material impact on the carrying value of assets and liabilities and the recognition of income and expenses. We consider these accounting estimates to be critical accounting estimates. The estimates and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances.
For a description of our estimates regarding our critical accounting estimates, see “Critical Accounting Estimates” in the 2026 10-K.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to our quantitative and qualitative disclosures about market risk during the three months ended September 30, 2026 from those disclosed in our 2026 10-K. See Part II, Item 7A of our 2026 Form 10-K for a detailed discussion of our market risks.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by
33
this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2026.
Changes in Internal Control Over Financial Reporting
There have been no changes in internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
34
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
For information regarding our material pending legal proceedings, refer to Note 9 “Commitments and Contingencies” to our condensed consolidated financial statements located in Part I, Item 1 of this report.
Item 1.A Risk Factors
In addition to the information set forth in this report, you should carefully consider the risk factors disclosed in Part I, Item 1A of our 2026 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
35
Item 6. Exhibits
The following is a list of all exhibits filed or furnished as part of this report:
EXHIBIT INDEX
| Exhibit No. | Description | |||||||
| 3.1 | ||||||||
| 3.2 | ||||||||
| 3.3 | ||||||||
31.1* | ||||||||
31.2* | ||||||||
| 32.1† | ||||||||
| 32.2† | ||||||||
| 101 | The following financial information from InnovAge Holding Corp's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 formatted in Inline XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets (unaudited), (ii) the Condensed Consolidated Statements of Operations (unaudited), (iii) the Condensed Consolidated Statements of Stockholders' Equity (unaudited), (iv) the Condensed Consolidated Statements of Cash Flows (unaudited), and (v) Notes to the Condensed Consolidated Financial Statements (unaudited). | |||||||
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) | |||||||
________________________
*Filed herewith.
†The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed “furnished” with this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.
36
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.
| INNOVAGE HOLDING CORP. | ||||||||
Date: November 3, 2026 | By: | /s/ Benjamin C. Adams | ||||||
| Name: | Benjamin C. Adams | |||||||
| Title: | Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer) | |||||||
37
Exhibit 31.1
Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
I, Patrick Blair, certify that:
1.I have reviewed this quarterly report on Form 10-Q of InnovAge Holding Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 3, 2026 | ||||||||
| By: | /s/ Patrick Blair | |||||||
| Name: | Patrick Blair | |||||||
| Title: | Chief Executive Officer | |||||||
Exhibit 31.2
Certification Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
I, Benjamin C. Adams, certify that:
1.I have reviewed this quarterly report on Form 10-Q of InnovAge Holding Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 3, 2026 | ||||||||
| By: | /s/ Benjamin C. Adams | |||||||
| Name: | Benjamin C. Adams | |||||||
| Title: | Chief Financial Officer | |||||||
Exhibit 32.1
Certification of Chief Executive Officer
Pursuant to Rule 18 U.S.C. Section 1350
In connection with the Quarterly Report on Form 10-Q of InnovAge Holding Corp. (the “Company”) for the fiscal quarter ended September 30, 2026 as filed with the U.S. Securities and Exchange Commission (the “Report”), I, Patrick Blair, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 3, 2026 | ||||||||
| By: | /s/ Patrick Blair | |||||||
| Name: | Patrick Blair | |||||||
| Title: | Chief Executive Officer | |||||||
Exhibit 32.2
Certification of Chief Financial Officer
Pursuant to Rule 18 U.S.C. Section 1350
In connection with the Quarterly Report on Form 10-Q of InnovAge Holding Corp. (the “Company”) for the fiscal quarter ended September 30, 2026 as filed with the U.S. Securities and Exchange Commission (the “Report”), I, Benjamin C. Adams, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 3, 2026 | ||||||||
| By: | /s/ Benjamin C. Adams | |||||||
| Name: | Benjamin C. Adams | |||||||
| Title: | Chief Financial Officer | |||||||